George O. Elston
Net Worth

Last updated:

What is George O. Elston net worth?

The estimated net worth of Mr. George O. Elston is at least $4,597,200 as of 25 May 2024. He owns shares worth $441,600 as insider and has received compensation worth at least $4,155,600 in EyePoint Pharmaceuticals, Inc..

What is the salary of George O. Elston?

Mr. George O. Elston salary is $692,600 per year as Chief Financial Officer & Head of Corporation Devel. in EyePoint Pharmaceuticals, Inc..

How old is George O. Elston?

Mr. George O. Elston is 60 years old, born in 1965.

What stocks does George O. Elston currently own?

As insider, Mr. George O. Elston owns shares in one company:

Company Title Shares Price per share Total value
EyePoint Pharmaceuticals, Inc. (EYPT) Chief Financial Officer & Head of Corporation Devel. 40,000 $11.04 $441,600

What does EyePoint Pharmaceuticals, Inc. do?

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

EYPT logo
EYPT
EyePoint Pharmaceuticals, Inc.
$11.04

George O. Elston insider trading

EyePoint Pharmaceuticals, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Restricted Stock Units 5,833 N/A N/A
Option
Common Stock 5,833 N/A N/A
Option
Common Stock 4,967 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Restricted Stock Units 15,285 N/A N/A
Option
Common Stock 15,285 N/A N/A
Option
Common Stock 5,833 N/A N/A
Option
Restricted Stock Units 5,833 N/A N/A
Option
Restricted Stock Units 4,967 N/A N/A
Option
Common Stock 4,967 N/A N/A
Option
Restricted Stock Units 4,966 N/A N/A
Option
Common Stock 4,966 N/A N/A
Purchase
Common Stock 10,000 $0.48 $4,800
Purchase
Common Stock 10,000 $0.61 $6,110
Purchase
Common Stock 10,000 $0.96 $9,600
Purchase
Common Stock 10,000 $1.43 $14,290

EyePoint Pharmaceuticals key executives

EyePoint Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: